Search





Search





Markets
/
Stocks
/
nasdaq-kzr
/

Kezar Life Sciences Inc

KZR

Add to Watchlist

7.290USD

0.0000.00%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

53.86MMarket Cap

LossP/E TTM



Kezar Life Sciences Inc

7.290

0.0000.00%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Kezar Life Sciences Inc

Currency: USD Updated: 2026-05-08

Key Insights

Kezar Life Sciences Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 142 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 6.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kezar Life Sciences Inc's Score

Industry at a Glance

Industry Ranking

142 / 384

Overall Ranking

280 / 4494

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Kezar Life Sciences Inc Highlights

StrengthsRisks

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The Company is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.

Undervalued

The company’s latest PE is -0.95, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 4.52M shares, decreasing 18.35% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 131.28K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

6.000

Target Price

-17.70%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-08

The current financial score of Kezar Life Sciences Inc is 7.83, ranking 60 out of 384 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

7.93

Change

-0.1



Financials

7.99

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.32

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.21

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Kezar Life Sciences Inc's Company Valuation

Currency: USD Updated: 2026-05-08

The current valuation score of Kezar Life Sciences Inc is 7.39, ranking 121 out of 384 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.95, which is -110.97% below the recent high of 0.10 and -7481.50% above the recent low of -72.17.

Score

Industry at a Glance

Previous score

7.39

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 142/384

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-08

The current earnings forecast score of Kezar Life Sciences Inc is 6.40, ranking 332 out of 384 in the Biotechnology & Medical Research industry. The average price target is 6.00, with a high of 7.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

6.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-08

The current price momentum score of Kezar Life Sciences Inc is 4.62, ranking 333 out of 384 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.46 and the support level at 7.16, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.90

Change

-0.28

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.040

Neutral

RSI(14)

52.548

Neutral

STOCH(KDJ)(9,3,3)

42.497

Sell

ATR(14)

0.116

Low Volatility

CCI(14)

41.586

Neutral

Williams %R

75.000

Sell

TRIX(12,20)

0.130

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

7.352

Sell

MA10

7.330

Sell

MA20

7.332

Sell

MA50

7.117

Buy

MA100

6.709

Buy

MA200

5.794

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of Kezar Life Sciences Inc is 5.00, ranking 132 out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 61.21%, representing a quarter-over-quarter increase of 4.70%. The largest institutional shareholder is The Vanguard, holding a total of 339.67K shares, representing 4.60% of shares outstanding, with 21.60% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BML Capital Management LLC

720.79K

Suvretta Capital Management, LLC

716.76K

Tang Capital Management, LLC

664.31K

-7.73%

Equal Talent Investments, Ltd.

616.50K

Nantahala Capital Management, LLC

276.75K

Affinity Asset Advisors LLC

229.08K

Stonepine Capital Management, LLC

156.18K

-59.24%

Renaissance Technologies LLC

Star Investors

131.28K

+13.29%

Risk Assessment

Currency: USD Updated: 2026-05-08

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Kezar Life Sciences Inc is 2.59, ranking 207 out of 384 in the Biotechnology & Medical Research industry. The company's beta value is 0.41. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.